Shuttle Pharma pivots to AI drug discovery, winds down trials, discloses control weaknesses

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Company acquired Molecule.ai AI platform in Nov 2025 and terminated Ropidoxuridine clinical trials, abandoning its founding radiation sensitizer program. Working capital swung from $3.2M surplus to $5.8M deficit, with $6.4M in acquisition-related payables outstanding.

  MD&A: Strategic Transactions verify on EDGAR →
• high

  Management notes it has identified material weaknesses in internal control over financial reporting in the past and may do so again in disclosure controls, including inadequate accounting policies, IT access controls, and failure to communicate material contracts timely. Remediation underway with external consultants but no completion timeline provided.

  Controls and Procedures verify on EDGAR →
• high

  R&D spending collapsed 83% to $0.3M as trials wound down, while G&A doubled to $1.2M driven by $0.6M quarterly amortization of Molecule.ai intangible asset and $0.1M in investor relations advertising. Company spent $4.75M on IR marketing across three agreements since April 2025.

  MD&A: Operating Expenses verify on EDGAR →